论文部分内容阅读
在更新风险管理计划(RMP)之后,欧洲药品管理局(EMA)药物警戒工作组(Ph-VWP)对吡美莫司批准适应症之外的使用进行了回顾。吡美莫司是一种外用的钙调神经磷酸酶抑制剂,被批准用于年龄不低于2岁,且不建议或无法使用(对皮质类固醇激素不耐受或缺乏疗效)外用皮质类固醇激素的轻至中度特应性皮炎患者的治
After updating the Risk Management Plan (RMP), the European Medicines Agency (EMA) Working Group on Phytosanitary Measures (Ph-VWP) reviewed the use of pimecrolimus approved indications. Pimecrolimus is a topical calcineurin inhibitor approved for use in individuals over the age of 2 years and is not recommended or inoperable (intolerance or lack of efficacy of corticosteroids) Topical corticosteroids Of patients with mild to moderate atopic dermatitis